Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Faruque, Labib Imran ^a   Lin, Meng ^a   Battistella, Marisa ^b   Wiebe, Natasha ^a   Reiman, Tony ^c   Hemmelgarn, Brenda ^d   Thomas, Chandra ^d   Tonelli, Marcello ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MOTESANIB; NAVELBINE; OGLUFANIDE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PREDNISOLONE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER THERAPY; CEREBROVASCULAR ACCIDENT; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MELANOMA; METASTATIC COLORECTAL CANCER; OVARY CANCER; PANCREAS CANCER; PANCREAS METASTASIS; PANCREATIC NEUROENDOCRINE TUMOR; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; UTERINE CERVIX CANCER; ADULT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); MEDLINE; NEOPLASMS; RISK FACTOR;

ADULT; ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; MEDLINE; MYOCARDIAL INFARCTION; NEOPLASMS; PROTEINURIA; RISK FACTORS; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903753621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101145     Document Type: Review

References (42)

1. Quesada AR, Medina MA, Alba E (2007) Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 29: 1159-1168.
2. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795. (Pubitemid 46912024)
3. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
4. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147. (Pubitemid 38524883)
5. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, et al. (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 110: 19059-19064.
6. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72: 402-407.
7. Moser C, Lang SA, Stoeltzing O (2007) The direct effects of anti-vascular endothelial growth factor therapy on tumor cells. Clin Colorectal Cancer 6: 564-571. (Pubitemid 47242432)
8. Gurevich F, Perazella MA (2009) Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 122: 322-328.
9. Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, et al. (2011) Bevacizumab treatment for advanced breast cancer. Oncologist 16: 1684-1697.
10. Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 7: CD008941.
11. FDA (2010) Avastin (bevacizumab): Process for Removal of Breast Cancer Indication Begun. Available: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm. Accessed: 2014 Apr 4.
12. FDA (2011) Proposal to withdraw approval for the breast cancer indication for Avastin (bevacizumab). Available: http://www.fda.gov/downloads/NewsEvents/ Newsroom/UCM280546.pdf. Accessed: 2014 April 4.
13. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
14. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, et al. (1981) A method for assessing the quality of a randomized control trial. Control Clin Trials 2: 31-49. (Pubitemid 11083624)
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
16. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412.
17. Cho MK, Bero LA (1996) The quality of drug studies published in symposium proceedings. Ann Intern Med 124: 485-489. (Pubitemid 26070113)
18. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, et al. (2010) Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 303: 1180-1187.
19. Keefe D, Bowen J, Gibson R, Tan T, Okera M, et al. (2011) Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 16: 432-444.
20. Copur MS, Obermiller A (2011) An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 10: 151-156.
21. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, et al. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815.
22. Bhargava P (2009) VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297: R1-5.
23. Evans T (2012) Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC. Anticancer Res 32: 4629-4638.
24. Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358: 95-97.
25. Snider KL, Maitland ML (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 4: 67-76.
26. Stylianou K, Lioudaki E, Papadimitraki E, Kokologiannakis G, Kroustalakis N, et al. (2011) Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant 26: 1742-1745.
27. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203-218. (Pubitemid 47095077)
28. Kelly RJ, Billemont B, Rixe O (2009) Renal toxicity of targeted therapies. Target Oncol 4: 121-133.
29. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
30. Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, et al. (2012) An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer 78: 1-7.
31. Hang XF, Xu WS, Wang JX, Wang L, Xin HG, et al. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 67: 613-623.
32. Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, et al. (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29: 1757-1764.
33. Yang K, Wang YJ, Chen XR, Chen HN (2010) Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 30: 229-241.
34. Liu F, Chen X, Peng E, Guan W, Li Y, et al. (2011) VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci 31: 799-806.
35. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 108: 1556-1563.
36. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, et al. (2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev: CD007930.
37. Elice F, Rodeghiero F (2012) Side effects of anti-angiogenic drugs. Thromb Res 129 Suppl 1: S50-53.
38. Dreyfus B, Kawabata H, Gomez A (2013) Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors. Cancer Epidemiol 37: 191-196.
39. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27-38.
40. Je Y, Schutz FA, Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10: 967-974.
41. Sharma K, Marcus JR (2013) Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. Ann Plast Surg 71: 434-440.
42. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, et al. (2009) A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 62: 707-709.